The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Transmucosal Drug Delivery Devices Market In 2026, And How Will Its Value Evolve By 2030?
The transmucosal drug delivery devices market has shown significant growth in recent years. Its size is expected to expand from $54.63 billion in 2025 to $59.61 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. Historically, this market expansion can be attributed to the rise of non-invasive drug delivery methods, increasing demand for pain management treatments, greater utilization of hormone replacement therapies, advancements in pharmaceutical formulation, and widespread acceptance of transmucosal applications.
Significant expansion is anticipated for the transmucosal drug delivery devices market size over the coming years. By 2030, this market is projected to reach $81.52 billion, expanding at a compound annual growth rate (CAGR) of 8.1%. Factors driving this growth during the projected period include the growing creation of personalized medicine solutions, increased capital allocation towards sophisticated drug delivery platforms, a surging need for home-based drug administration tools, the broadening scope of biologics and peptide-based medications, and more frequent regulatory endorsements for innovative delivery mechanisms. Key developments expected within this timeframe encompass the wider acceptance of buccal and sublingual administration methods, an escalating requirement for quickly acting drug delivery, the advancement of microneedle and active delivery innovations, an elevated focus on user-friendly drug delivery devices, and a heightened priority on precise dosing and biological availability.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Transmucosal Drug Delivery Devices Market Demand?
The increasing incidence of long-term illnesses is anticipated to boost the expansion of the transmucosal drug delivery devices market in the foreseeable future. A chronic disease describes an enduring medical state that usually advances gradually and endures for an extended period, frequently demanding continuous medical intervention to manage its indicators and avert complications. The rise in chronic diseases stems from factors such as lifestyle choices, an aging global populace, environmental influences, difficulties within healthcare systems, and increasing urbanization. In the context of chronic diseases, transmucosal drug delivery devices are employed to facilitate precise and effective medication administration, thereby maintaining consistent therapeutic concentrations essential for symptom management and enhancing patient compliance. As an illustration, the National Health Service, a governmental body in the UK, reported in June 2024 that 3,615,330 people registered with a general practitioner (GP) had received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This represented an 18% rise from the 3,065,825 instances recorded in 2022. Consequently, the increasing occurrence of chronic illnesses is propelling the transmucosal drug delivery devices market.
What Are The Key Segment Divisions In The Transmucosal Drug Delivery Devices Market Segment Structure?
The transmucosal drug delivery devices market covered in this report is segmented –
1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals
Subsegments:
1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films
2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays
3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators
4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels
5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels
What Trends Are Influencing Changes In The Transmucosal Drug Delivery Devices Market?
Leading companies in transmucosal drug delivery devices are creating innovative smart platforms, such as unique transdermal patch delivery systems, which are designed to enhance drug absorption and improve patient compliance and convenience. These proprietary transdermal patch delivery platforms are specialized technologies owned by companies for administering medications through the skin, ensuring controlled release and improved therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, introduced STARSILON, a novel proprietary transdermal patch delivery platform, intended for extended duration to achieve therapeutic delivery of difficult-to-formulate APIs. This development expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.
Which Organizations Are Engaged In The Transmucosal Drug Delivery Devices Market?
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd
Get The Full Transmucosal Drug Delivery Devices Market Report:
Which Region Leads The Transmucosal Drug Delivery Devices Market In Overall Market Size?
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Transmucosal Drug Delivery Devices Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2026, By The Business Research Company
Oral Transmucosal Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report
Drug Delivery Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Drug Delivery Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model